Amgen Appoints Vance D. Coffman to the Company's Board of Directors
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 2, 2007--Amgen
(NASDAQ:AMGN) announced today that its Board of Directors has
appointed Vance D. Coffman to the Company's Board. Coffman, 63, is the
former chairman and chief executive officer of Lockheed Martin
Corporation. The addition of Coffman brings the number of Amgen Board
members to 11.
Coffman was elected chairman of Lockheed in April 1998, having
served as CEO and vice chairman since August 1997. Previously, he
served in a number of elected corporate leadership positions including
president and chief operating officer of Lockheed Martin's Space &
Strategic Missile Sector. Coffman currently serves on the boards of
Deere & Company and 3M Company.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a deep and broad pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
CONTACT: Amgen, Thousand Oaks
David Polk, 805-447-4613 (media)
Arvind Sood, 805-447-1060 (investors)